LOS ANGELES - TelAve -- Researchers have reanalyzed data from a $35 million U.S. National Institute of Mental Health (NIMH)-funded study, challenging its conclusions and raising further concerns about flaws in antidepressant research. Published in BMJ, the study debunks the 2006 Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which claimed a 67% depression remission rate for antidepressants. Instead, it suggests a success rate of only 35%—only half of what was previously thought—questioning past psychiatric research and treatment decisions.[1] Indeed, other studies also indicate that antidepressants may be largely ineffective and potentially harmful. The mental health industry watchdog, Citizens Commission on Human Rights International, says this is another example of inflated results about antidepressant efficacy, which can mislead consumers into taking antidepressants and could be a driving force behind why 45 million Americans currently take the drugs.

The BMJ authors concluded that "STAR*D's cumulative remission rate was approximately half of that reported" originally and response rates were significantly inflated.

In an article in the Psychiatric Times titled "The STAR*D Dethroned?," the author, John J. Miller, M.D. stated, "For us in psychiatry, if the BMJ authors are correct, this is a huge setback, as all of the publications and policy decisions based on the STAR*D findings that became clinical dogma since 2006 will need to be reviewed, revisited, and possibly retracted."

Michael P. Hengartner from the Department of Applied Psychology, Zurich University of Applied Sciences in Switzerland, analyzed discontinuation trials focusing on the efficacy of antidepressants in maintenance therapy, finding them questionable. He also found that "a growing body of evidence from hundreds of randomized controlled trials suggests that antidepressants cause suicidality, but this risk is underestimated because data from industry-funded trials are systematically flawed. The strong reliance on industry-funded research results in an uncritical approval of antidepressants." The harm, he added, "is systematically underestimated."[2]

More on TelAve News

• Over 98% of crypto owners globally don't declare taxes, new report find
• TicTac Group acquires French EdTech company Distrisoft
• Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
• Genpak Announces Closure of Utah Manufacturing Facility
• Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap

Such potential harm was flagged in 2022 when a major study by researchers at the University College of London disproved the decades-old theory that a brain-based chemical abnormality causes depression requiring antidepressants to correct it.[3]  Since the early 1990s, the industry has propagated this fabricated theory, and as lead author Professor Joanna Moncrieff, M.D. said, "The popularity of the 'chemical imbalance' theory has coincided with a huge increase in the use of antidepressants."[4]

In 2018, Prof. Moncrieff was asked to review the first reports of the primary outcome measure of STAR*D, 14 years after the study was finished. "The paper I was asked to review, which is now published in Psychology of Consciousness: Theory, Research and Practice, is written by a group led by Irving Kirsch and based on the original data obtained through the NIMH."

"Whatever the reason," she said, based on the follow-up, "people taking antidepressants do not do very well. In fact, given that for the vast majority of people depression is a naturally remitting condition, it is difficult to believe that people treated with antidepressants do any better than people who are offered no treatment at all."[5]

Ed Pigott, Ph.D., added this: "Before STAR*D, I wasn't prone to believing in conspiracy theories but as we peeled back its layers I found myself spinning theories about how this study became so profoundly misrepresented given all of the actors involved (20+ top-tier researchers/NIMH), anyone of whom could have objected and 'blown the whistle;' but none did." He went a great deal further saying STAR*D's results were "falsely portrayed in ways that harm those who suffer with depression."[6]

Pigott cited Thomas Insel, head of NIMH, who observed that "The unfortunate reality is that current medications help too few people to get better and very few people to get well."

"What a sad commentary on the 50+ years of psychotropic drug research efforts," Piggot wrote.

Thirteen of the 16 authors of the original STAR*D study reported financial affiliations with numerous pharmaceutical companies, including Bristol-Myers Squibb, Forest Laboratories, GlaxoSmithKline, Organon, Pfizer, and King Pharmaceuticals and Wyeth that provided medications at no cost for this trial.[7]

More on TelAve News

• The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
• Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
• Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
• New Book Reveals The Science Of Predictions
• Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews

Indeed, the lead researcher was under U.S. Senate investigation in 2008 for his undisclosed conflicts of interest for reporting only $3,000 of the nearly $18,000 that Eli Lilly, the manufacturer of antidepressants, paid him in 2001. Between 2000 and 2007, he failed to report another $12,000 from various drug companies.[8] That inquiry, headed by Senator Charles Grassley, looked at seven psychiatrists who had failed to declare nearly $9.9 million between them to universities and agencies with whom they worked and who required such disclosure.[9]

Because of the serious potential harm psychotropic drugs can cause, CCHR says flawed studies should be retracted and independently investigated for consumer fraud.

About CCHR: CCHR was founded in 1969 by the Church of Scientology and the late Dr. Thomas Szasz, Professor of Psychiatry and prolific author of books on psychiatry. It successfully campaigned for the FDA black box warning about antidepressant-induced suicide.

Sources:

[1] www.psychiatrictimes.com/view/star-d-dethroned

[2] www.ncbi.nlm.nih.gov/pmc/articles/PMC5725408/

[3] www.cchrint.org/2022/08/19/with-the-chemical-imbalance-myth-exposed-thats-not-all-psychiatry-got-wrong/ citing www.nature.com/articles/s41380-022-01661-0

[4] www.cchrint.org/2022/07/22/cchr-lauds-study-disproving-chemical-imbalance-causes-depression/ citing www.dailymail.co.uk/news/article-11035903/Expert-says-psychiatrists-KNOW-theory-low-serotonin-levels-cause-depression-incomplete.html; www.nature.com/articles/s41380-022-01661-0

[5] www.madinamerica.com/2018/10/results-world-largest-antidepressant-study-look-dismal/

[6] www.madinamerica.com/2011/03/%EF%BB%BFan-introduction-the-story-of-bias-in-the-stard-trial-more/

[7] John Rush, et al., "Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report," American Journal of Psychiatry, 2006

[8] www.cchrint.org/2010/05/21/dsm-panel-members-still-getting-pharma-funds/; globalhealth.duke.edu/news/dr-augustus-john-rush-joins-duke-nus-graduate-medical-school-vice-dean-clinical-sciences

[9] www.cchrint.org/issues/psycho-pharmaceutical-front-groups/dbsa-advisory-board/